Up-to-date Information on
Waldenström’s macroglobulinemia



The state-of-the-art glossary for Waldenström’s macroglobulinemia.


Bortezomib in the glossary for Waldenström's macroglobulinemia

Bortezomib is a proteosome inhibitor.

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. Inhibition of the proteasome results in cell cycle arrest and apoptosis. Bortezomib is administered as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone. Bortezomib is indicated for the treatment of multiple myeloma and lymphoma. Bortezomib was approved for medical use in the United States in 2003 and in the European Union in 2004 (Bortezomib SmPC).

Glossary overview